Diagnostic utility of phosphatase and tensin homolog, β-catenin, and p53 for endometrial carcinoma by thin-layer endometrial preparations

Cancer

Volumn 114, Issue 3, 2008, Pages 155-164

  Norimatsu, Yoshiaki ^a,b   Miyamoto, Motoyuki ^a   Kobayashi, Tadao K ^c   Moriya, Takuya ^d   Shimizu, Keiko ^e   Yanoh, Kenji ^f   Tsukayama, Choutatsu ^a   Miyake, Yasuyuki ^b   Ohno, Eiji ^b  

^a KURASHIKI CENTRAL HOSPITAL   (Japan)

^b KURASHIKI UNIVERSITY OF SCIENCE AND THE ARTS   (Japan)

^c Medical Care Center   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

^e Utsunomiya Hospital   (Japan)

^f SUZUKA GENERAL HOSPITAL   (Japan)

Author keywords

catenin; Endometrial carcinoma; Endometrial cytology; Immunocytochemistry; P53; Phosphatase and tensin homolog; Thin layer preparations

Indexed keywords

BETA CATENIN; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER GRADING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENDOMETRIUM ATROPHY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE PREPARATION;

ADENOCARCINOMA; ADULT; AGED; BETA CATENIN; CARCINOMA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HISTOLOGICAL TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PTEN PHOSPHOHYDROLASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 47049120566     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23495     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Oncology Committee. Annual report on cervical, endometrial, and ovarian cancer. Acta Obstet Gynaecol Jpn. 2004;58:1641-1726.
3. Nakagawa-Okamura C, Sato S, Tsuji I, et al. Effectiveness of mass screening for endometrial cancer. Acta Cytol. 2002;46:277-283.
4. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004;444:213-223.
5. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2005;24:4783-4791.
6. Weintraub J, Morabia A. Efficacy of a liquid-based thin-layer method for cervical cancer screening in a population with a low incidence of cervical cancer. Diagn Cytopathol. 2000;22:52-59.
7. Michael CW, Hunter B. Interpretation of fine-needle aspirates processed by the ThinPrep technique: cytologic artifacts and diagnostic pitfalls. Diagn Cytopathol. 2000;23:6-13.
8. Norimatsu Y, Kouda H, Kobayashi TK, et al. Utility of thin-layer preparations in the endometrial cytology: evaluation of benign endometrial lesions. Ann Diagn Pathol. 2008;12:103-111.
9. Buccoliero AM, Gheri CF, Castiglione F, et al. Liquid-based endometrial cytology: cyto-histological correlation in a population of 917 women. Cytopathology. 2007;18:241-249.
10. Norimatsu Y, Miyamoto T, Kobayashi TK, et al. Utility of thin-layer preparations in the endometrial cytology: immunocytochemical expression of PTEN, beta-catenin and p53 for benign endometrial lesions. Diagn Cytopathol. 2008;36:216-223.
11. Norimatsu Y, Kouda H, Kobayashi TK, et al. Utility of liquid-based cytology in the endometrial lesions: diagnosis of endometrial carcinoma. Cytopathology. In press.
12. Tripath Imaging, Inc. The PrepStain™ System operator's manual for in vitro diagnostic use. Burlington, NC: TriPath Imaging, Inc.; 2003.
13. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94:642-646.
14. Weng L, Brown J, Eng C. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and - independent pathways. Hum Mol Genet. 2001;10:237-242.
15. Sun H, Enomoto T, Fujita M, et al. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol. 2001;115:32-38.
16. Hale GE, Hughes CL, Cline JM. Endometrial cancer: hormonal factors, the perimenopausal window of risk, and isoflavones. J Clin Endocrinol Metab. 2002;87:3-15.
17. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92:924-930.
18. Mutter GL, Ince TA, Baak JPA, Kust G, Zhou X, Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res. 2001;61:4311-4314.
19. Kanamori Y, Kigawa J, Itamochi H, et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res. 2001;7:892-895.
20. Athanassiadou P, Athanassiades P, Grapsa D, et al. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study. Int J Gynecol Cancer. 2007;17:697-704.
21. Kimura F, Watanabe J, Hata H, et al. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol. 2004;130:161-168.
22. Salvesen HB, Stefansson I, Kretzschmar EI, et al. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol. 2004;25:1615-1623.
23. Inaba F, Kawamata H, Teramoto T, Fukasawa I, Inaba N, Fujimori T. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma. Oncol Rep. 2005;13:17-24.
24. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 1999;96:5522-5527.
25. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S. Beta-catenin mutations in carcinoma of the uterine endometrium. Cancer Res. 1998;58:3526-3528.
26. Machin P, Catasus L, Pons C, Munoz J, Matias-Guiu X, Prat J. CTNNB1 mutations and β-catenin expression in endometrial carcinomas. Hum Pathol. 2002;33:206-212.
27. Shih HC, Shiozawa T, Miyamoto T, et al. Nuclear localization of beta-catenin is correlated with the expression of cyclin D1 in endometrial carcinomas. Anticancer Res. 2003;23:3749-3754.
28. Saegusa M, Hashirnura M, Kuwata T. Hamano M, Okayasu I. Beta-catenin simultaneously induces activation of the p53-p21WAFI path-way and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells. Am J Pathol. 2004;164:1739-1749.
29. Shih HC, Shiozawa T, Miyamoto T, et al. Immunohistochemical expression of E-cadherin and beta-catenin in the normal and malignant human endometrium: an inverse correlation between E-cadherin and nuclear beta-catenin expression. Anticancer Res. 2004;24:3843-3850.
30. Scholten AN, Aliredjo R, Creutzberg CL, Smit VT. Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma. Int J Gynecol Cancer. 2006;16:1379-1385.
31. Lane DP. Cancer, p53, guardian of the genome. Nature. 1992;358:15-16.
32. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-Ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88:814-824.
33. Shih HC, Shiozawa T, Kato K, et al. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol. 2003;34:471-478.